long intergenic non-protein coding RNA 2708Genealiases: []
Q-omics provides the consensus-scored LINC02708 profile across patient tissues and cancer cell-line models. LINC02708 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC02708 is differentially expressed in 3, with the highest sampling consensus in BLCA. Additionally, LINC02708 RNA expression shows 7,398 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, and TGCT as cancer lineages where LINC02708 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02708 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02708 survival associations across molecular data types. LINC02708 RNA expression shows survival associations in the most cancer types (15), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02708 RNA expression–survival associations across cancer types. High LINC02708 expression shows unfavorable associations in BLCA, HNSC, CHOL, UCEC, STAD and KICH. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC02708 RNA expression.
This table summarizes LINC02708 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02708. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02708 shows lower tumor expression in BLCA, CHOL and LIHC. The BLCA box plot shows higher LINC02708 RNA expression in normal versus tumor tissue (log2 FC = −0.098, t-test p = .017).
This table shows molecular features associated with LINC02708 in patient tissues and cancer cell lines. In patient samples, LINC02708 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
